This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In the larger public and population health context, on the patient side, we can expect the burden of disease beyond COVID to increase due to postponed care and treatment backlogs. for example, for heart disease and cardiovascular complications as well as for cancers. This has been found to be the case in the U.S.,
When this occurred, it didn’t cause more than a ripple of interest outside biotech. One can probably find examples of and exceptions to that at your local gas station. But the U.S. citizens’ personal data. Sure, there are exceptions to that, but there are exceptions to that at EVERY organization.
In my book, I highlight EpiPen and insulin prices as current examples of patient-consumer uproar, taking the patient-facing costs of these two life-sustaining therapies as quite personal. “A therapy is useless if no one can afford it,” asserted Cathryn Donaldson from AHIP, the health insurance advocacy group, quoted in the story.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content